Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro ... selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against ...

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...

Eli Lilly will launch studies to investigate whether its weight loss medications can help control addictive behaviors such as smoking and alcohol and drug abuse, CEO Dave Ricks revealed in a Dec ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Eli Lilly said on Wednesday ... Zepbound helped patients lose an average of 20% of their weight after 72 weeks compared to 14% for the group treated with Wegovy, Lilly said. Participants were ...

Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.

Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...